OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
Abdolreza Esmaeilzadeh, Reza Elahi
Journal of Cellular Physiology (2020) Vol. 236, Iss. 4, pp. 2519-2543
Open Access | Times Cited: 89
Abdolreza Esmaeilzadeh, Reza Elahi
Journal of Cellular Physiology (2020) Vol. 236, Iss. 4, pp. 2519-2543
Open Access | Times Cited: 89
Showing 1-25 of 89 citing articles:
COVID-19 and autoimmune diseases
Yu Liu, Amr H. Sawalha, Qianjin Lu
Current Opinion in Rheumatology (2020) Vol. 33, Iss. 2, pp. 155-162
Open Access | Times Cited: 441
Yu Liu, Amr H. Sawalha, Qianjin Lu
Current Opinion in Rheumatology (2020) Vol. 33, Iss. 2, pp. 155-162
Open Access | Times Cited: 441
COVID‐19: Virology, biology and novel laboratory diagnosis
Malihe Mohamadian, Hossein Chiti, Alireza Shoghli, et al.
The Journal of Gene Medicine (2020) Vol. 23, Iss. 2
Open Access | Times Cited: 350
Malihe Mohamadian, Hossein Chiti, Alireza Shoghli, et al.
The Journal of Gene Medicine (2020) Vol. 23, Iss. 2
Open Access | Times Cited: 350
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Evgeni Gusev, Alexey Sarapultsev, Л. В. Соломатина, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1716-1716
Open Access | Times Cited: 224
Evgeni Gusev, Alexey Sarapultsev, Л. В. Соломатина, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1716-1716
Open Access | Times Cited: 224
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 139
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 139
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 66
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 66
RETRACTED: Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients
Safa Tahmasebi, Mohamed A. El‐Esawi, Zaid Hameed Mahmoud, et al.
Journal of Cellular Physiology (2020) Vol. 236, Iss. 7, pp. 5325-5338
Closed Access | Times Cited: 109
Safa Tahmasebi, Mohamed A. El‐Esawi, Zaid Hameed Mahmoud, et al.
Journal of Cellular Physiology (2020) Vol. 236, Iss. 7, pp. 5325-5338
Closed Access | Times Cited: 109
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 61
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 61
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 45
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 45
OMICRON: Virology, immunopathogenesis, and laboratory diagnosis
Mahsa Bazargan, Reza Elahi, Abdolreza Esmaeilzadeh
The Journal of Gene Medicine (2022) Vol. 24, Iss. 7
Open Access | Times Cited: 42
Mahsa Bazargan, Reza Elahi, Abdolreza Esmaeilzadeh
The Journal of Gene Medicine (2022) Vol. 24, Iss. 7
Open Access | Times Cited: 42
Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms
Ameneh Jafari, Fahima Danesh Pouya, Zahra Niknam, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 6, pp. 4943-4957
Open Access | Times Cited: 41
Ameneh Jafari, Fahima Danesh Pouya, Zahra Niknam, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 6, pp. 4943-4957
Open Access | Times Cited: 41
Renal Injury by SARS-CoV-2 Infection: A Systematic Review
Mo Wang, Hua-Ying Xiong, Han Chen, et al.
Kidney Diseases (2020) Vol. 7, Iss. 2, pp. 100-110
Open Access | Times Cited: 63
Mo Wang, Hua-Ying Xiong, Han Chen, et al.
Kidney Diseases (2020) Vol. 7, Iss. 2, pp. 100-110
Open Access | Times Cited: 63
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 6
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 6
Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
Decsa Medika Hertanto, Bayu Satria Wiratama, Henry Sutanto, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 3419-3428
Open Access | Times Cited: 35
Decsa Medika Hertanto, Bayu Satria Wiratama, Henry Sutanto, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 3419-3428
Open Access | Times Cited: 35
Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions
E. Alperay Tarim, Müge Anıl-İnevi, Ilayda Ozkan, et al.
Biomedical Microdevices (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 16
E. Alperay Tarim, Müge Anıl-İnevi, Ilayda Ozkan, et al.
Biomedical Microdevices (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 16
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Mohd. Iqbal Yatoo, Zeenat Hamid, IZHAR AHMAD RATHER, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 7, pp. 1897-1909
Open Access | Times Cited: 32
Mohd. Iqbal Yatoo, Zeenat Hamid, IZHAR AHMAD RATHER, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 7, pp. 1897-1909
Open Access | Times Cited: 32
Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
Lara Herrera, Myriam Martin‐Inaraja, Silvia J. Santos, et al.
Immunology (2021) Vol. 165, Iss. 2, pp. 234-249
Open Access | Times Cited: 30
Lara Herrera, Myriam Martin‐Inaraja, Silvia J. Santos, et al.
Immunology (2021) Vol. 165, Iss. 2, pp. 234-249
Open Access | Times Cited: 30
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Cellular metabolic basis of altered immunity in the lungs of patients with COVID-19
Shuangyan Li, Fuxiaonan Zhao, Jing Ye, et al.
Medical Microbiology and Immunology (2022) Vol. 211, Iss. 1, pp. 49-69
Open Access | Times Cited: 19
Shuangyan Li, Fuxiaonan Zhao, Jing Ye, et al.
Medical Microbiology and Immunology (2022) Vol. 211, Iss. 1, pp. 49-69
Open Access | Times Cited: 19
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2
Mahnaz Ghaebi, Safa Tahmasebi, Maryam Jozghorbani, et al.
Life Sciences (2021) Vol. 277, pp. 119503-119503
Open Access | Times Cited: 23
Mahnaz Ghaebi, Safa Tahmasebi, Maryam Jozghorbani, et al.
Life Sciences (2021) Vol. 277, pp. 119503-119503
Open Access | Times Cited: 23
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, et al.
Cytokine & Growth Factor Reviews (2021) Vol. 60, pp. 28-45
Open Access | Times Cited: 23
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, et al.
Cytokine & Growth Factor Reviews (2021) Vol. 60, pp. 28-45
Open Access | Times Cited: 23
A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection
Ashraf A. Tabll, Yasser E. Shahein, Mohamed M. Omran, et al.
Human Antibodies (2021) Vol. 29, Iss. 3, pp. 179-191
Closed Access | Times Cited: 21
Ashraf A. Tabll, Yasser E. Shahein, Mohamed M. Omran, et al.
Human Antibodies (2021) Vol. 29, Iss. 3, pp. 179-191
Closed Access | Times Cited: 21
Endocrine and metabolic complications of COVID-19: lessons learned and future prospects
Abdolreza Esmaeilzadeh, Reza Elahi, Amir Siahmansouri, et al.
Journal of Molecular Endocrinology (2022) Vol. 69, Iss. 3, pp. R125-R150
Open Access | Times Cited: 15
Abdolreza Esmaeilzadeh, Reza Elahi, Amir Siahmansouri, et al.
Journal of Molecular Endocrinology (2022) Vol. 69, Iss. 3, pp. R125-R150
Open Access | Times Cited: 15
Targeting the cGAS-STING pathway as an inflammatory crossroad in coronavirus disease 2019 (COVID-19)
Reza Elahi, Salar Hozhabri, Amirhosein Moradi, et al.
Immunopharmacology and Immunotoxicology (2023) Vol. 45, Iss. 6, pp. 639-649
Closed Access | Times Cited: 9
Reza Elahi, Salar Hozhabri, Amirhosein Moradi, et al.
Immunopharmacology and Immunotoxicology (2023) Vol. 45, Iss. 6, pp. 639-649
Closed Access | Times Cited: 9
